We are finding the highest prevalence of human papillomavirus (HPV) among women in their early 20s, but the FDA now recommends that an HPV vaccine be administered to women up to the age of 45. Why? Because recent research tells us that the at-risk population may be larger than we think. Dr. Sharmila Makhija, associate professor of gynecologic oncology at Emory University School of Medicine, weighs the pros and cons of this new recommendation with host Dr. Lauren Streicher.